EMA/380478/2023

European Medicines Agency decision

P/0352/2023

of 8 September 2023

on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (Tavneos), (EMEA-002023-PIP01-16-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0352/2023

of 8 September 2023

on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (Tavneos), (EMEA-002023-PIP01-16-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0082/2017 issued on 22 May 2017, decision P/0268/2017 issued on 7 September 2017, decision P/0344/2017 issued on 23 November 2017, decision P/0360/2019 issued on 4 November 2019, decision P/0103/2020 issued on 20 March 2020, decision P/0181/2021 issued on 10 May 2021 and the decision P/0266/2022 issued on 27 July 2022,

Having regard to the application submitted by ChemoCentryx Ireland Ltd. on 21 April 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for avacopan (Tavneos), age-appropriate oral liquid dosage form, capsule, hard, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for avacopan (Tavneos), age-appropriate oral liquid dosage form, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to ChemoCentryx Ireland Ltd., 70 Sir John Rogerson's Quay, Dublin 2 - Dublin, Ireland.

EMA/PDCO/192650/2023 Corr. [1]
Amsterdam, 21 July 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002023-PIP01-16-M07

Scope of the application

Active substance(s):

Avacopan

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis

Pharmaceutical form(s):

Age-appropriate oral liquid dosage form

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

ChemoCentryx Ireland Ltd.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, ChemoCentryx Ireland Ltd. submitted to the European Medicines Agency on 21 April 2023 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0082/2017 issued on 22 May 2017, decision P/0268/2017 issued on 7 September 2017, decision P/0344/2017 issued on 23 November 2017, decision P/0360/2019 issued on 4 November 2019, decision P/0103/2020 issued on 20 March 2020, decision P/0181/2021 issued on 10 May 2021 and the decision P/0266/2022 issued on 27 July 2022.

[1] 18 August 2023

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver.

The procedure started on 22 May 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

The pharmaceutical form was amended.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;
   - to grant a waiver for one or more subsets of the paediatric population concluded in accordance with Article 11(1)(c) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- age-appropriate oral liquid dosage form, capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition

Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with active microscopic polyangiitis (MPA)

Treatment of patients with active granulomatosis with polyangiitis (GPA) where treatment with rituximab or cyclophosphamide containing regimen is indicated

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral liquid dosage form

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** *Deleted during procedure EMEA-002023-PIP01-16-M07* **Study 2** Development of age-appropriate oral liquid dosage form for use in the paediatric population from 6 years to less than 18 years of age
Non-clinical studies	**Study 3** 44 week nasogastric / oral toxicity study in cyno monkeys with 6-week recovery

	Study 4 Determination of PK parameters of the age-appropriate oral solid dosage form and the age-appropriate oral liquid dosage form in dogs **Study 5** 13-week oral toxicity study in juvenile hamsters with 4-week recovery phase
Clinical studies	**Study 6** Double-blind, double-dummy, randomised, placebo-controlled trial to evaluate safety and efficacy of avacopan as add-on to standard of care compared to prednisone in children from 12 to less than 18 years of age (and adults) with active anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis **Study 7** Open-label, 3-period, 3-way, crossover, single-dose bioavailability study in adult healthy volunteers to evaluate the PK profile of liquid paediatric formulation **Study 8** *Deleted during procedure EMEA-002023-PIP01-16-M07* **Study 9** *Deleted during procedure EMEA-002023-PIP01-16-M07* **Study 14** *Added during procedure EMEA-002023-PIP01-16-M07* Open label, uncontrolled single-arm study to evaluate pharmacokinetics, safety and activity of avacopan as add-on to standard of care in children from 6 years to less than 18 years of age with active ANCA-associated vasculitis
Extrapolation, modelling and simulation studies	**Study 10** Population PK modelling to support dosing in adolescents from 12 to less than 18 years of age **Study 11** Population PK modelling to support dosing in children from 6 to less than 12 years of age **Study 12** Deleted during procedure EMEA-002023-PIP01-16-M07 **Study 13** Extrapolation study to provide efficacy assumptions in the paediatric population from 6 years to less than 18 years of age with active ANCA-associated vasculitis based on extrapolation from adult population
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis

Authorised indication(s):

- In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
  - Invented name(s): Tavneos
  - Authorised pharmaceutical form(s): Capsule, hard
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure